AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19489187 — intervention group
Group type: EXPERIMENTAL
Intervention: New toothpaste containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride (MFP)
Number of subjects: 77
Study 19489187 — intervention group
Group type: COMPARATOR
Intervention: Commercial sensitive toothpaste containing 2% potassium ion and 1450 ppm fluoride (NaF)
Number of subjects: 77
Study 17823446 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy intervention group (n = 39) receiving daily approximately 1200 mg Ca and 7.5 microg vitamin D3 via fortified dairy products and biweekly nutrition education sessions
Number of subjects: 101
Study 17823446 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium‐supplemented group (n = 26) receiving a total of 1200 mg Ca/d
Number of subjects: 101
Study 17823446 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 101
Study 15114779 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular heparin dalteparin (n = 31)
Number of subjects: 51
Study 15114779 — intervention group
Group type: COMPARATOR
Intervention: Non-fractionated heparin (n = 17)
Number of subjects: 51
Study 11711015 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation of an academic research group in the study
Number of subjects: 165
Study 11711015 — intervention group
Group type: EXPERIMENTAL
Intervention: Research topic
Number of subjects: 165
Study 11711015 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive
Number of subjects: 165
Study 11711015 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional obligation
Number of subjects: 165
Study 11711015 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment
Number of subjects: 165
Study 9556902 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch containing 4.0 mg of E2 in a reservoir system
Number of subjects: 10
Study 9556902 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch containing 1.8 mg of E2 in a specially designed matrix system
Number of subjects: 10
Study 9556902 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix system patches
Number of subjects: 10
Study 7575171 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracentesis with Dextran‐70
Number of subjects: 20
Study 7575171 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 20
Study 2623709 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc‐Fluorid‐Hexetidin mouthrinse
Number of subjects: 0
Study 2623709 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidin (positive control)
Number of subjects: 0
Study 2623709 — intervention group
Group type: COMPARATOR
Intervention: Experimental gingivitis (negative control)
Number of subjects: 0
Study 31339815 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient burnout prevention program (three-week duration, including stress management interventions, relaxation, physical exercise, moor baths, and massage)
Number of subjects: 80
Study 31339815 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient burnout prevention program
Number of subjects: 80
Study 31722135 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of α-lipoic acid
Number of subjects: 0
Study 31722135 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid supplementation
Number of subjects: 0
Study 31722135 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid
Number of subjects: 0
Study 28118185 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD lesions
Number of subjects: 50
Study 25904367 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly rifapentine plus isoniazid (3HP)
Number of subjects: 7552
Study 25904367 — intervention group
Group type: COMPARATOR
Intervention: Daily isoniazid (9H)
Number of subjects: 7552
Study 23908125 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 219
Study 23908125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 21212920 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge assessment regarding Ecstasy (MDMA)
Number of subjects: 4116
Study 21212920 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude assessment regarding Ecstasy (MDMA)
Number of subjects: 4116
Study 21212920 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice assessment regarding Ecstasy (MDMA)
Number of subjects: 4116
Study 21212920 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between knowledge and attitude
Number of subjects: 4116
Study 21212920 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between attitude and practice
Number of subjects: 4116
Study 19552744 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (7 days) with antibiotics (clarithromycin and amoxicillin) given on days 1-4, 4-7, or 1-7
Number of subjects: 100
Study 17653421 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted training (Group B)
Number of subjects: 60
Study 17653421 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom training (Group A)
Number of subjects: 60
Study 15497665 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg test tablets
Number of subjects: 0
Study 15497665 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg test tablets
Number of subjects: 0
Study 15497665 — intervention group
Group type: COMPARATOR
Intervention: Reference tablets of the same strength (250 mg and 500 mg)
Number of subjects: 0
Study 11456368 — intervention group
Group type: EXPERIMENTAL
Intervention: 89Sr‐chloride (527 treatments)
Number of subjects: 510
Study 11456368 — intervention group
Group type: EXPERIMENTAL
Intervention: 186Re‐HEDP (83 treatments)
Number of subjects: 510
Study 11456368 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatments (up to five injections, 100 total)
Number of subjects: 510
Study 11456368 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 510
Study 11456368 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatments
Number of subjects: 510
Study 10923463 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg administered at 60 seconds
Number of subjects: 32
Study 10923463 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium maintenance (either intravenous infusion or bolus injection)
Number of subjects: 32
Study 10923463 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg administered at 90 seconds
Number of subjects: 32
Study 8038351 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily
Number of subjects: 28
Study 8038351 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg four times daily
Number of subjects: 28
Study 8038351 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 28
Study 2499730 — intervention group
Group type: EXPERIMENTAL
Intervention: ubinon (90 and 135 mg/day)
Number of subjects: 75
Study 2499730 — intervention group
Group type: EXPERIMENTAL
Intervention: ubinon
Number of subjects: 75
Study 2499730 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study 31829404 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumour resection plus chemotherapy
Number of subjects: 280
Study 31829404 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 280
Study 31200891 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus education
Number of subjects: 625
Study 31200891 — intervention group
Group type: COMPARATOR
Intervention: Education-only
Number of subjects: 625
Study 27443525 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary disease management program (MDP)
Number of subjects: 355
Study 27443525 — intervention group
Group type: COMPARATOR
Intervention: No MDP
Number of subjects: 355
Study 25863601 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social support
Number of subjects: 131
Study 25863601 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance support
Number of subjects: 131
Study 25863601 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance Support Measure
Number of subjects: 131
Study 24151394 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy alone (O‐G+t group)
Number of subjects: 391
Study 24151394 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy and mouthrinse treatment (O+G+tm group)
Number of subjects: 391
Study 24151394 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy, mouthrinse, and periodontal treatment (O+G+tmp group)
Number of subjects: 391
Study 24151394 — intervention group
Group type: COMPARATOR
Intervention: Control group (volunteers without discomfort)
Number of subjects: 391
Study 24151394 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐G+t group
Number of subjects: 391
Study 24151394 — intervention group
Group type: EXPERIMENTAL
Intervention: O+G+t group
Number of subjects: 391
Study 24151394 — intervention group
Group type: EXPERIMENTAL
Intervention: O+G+tm group
Number of subjects: 391
Study 24151394 — intervention group
Group type: EXPERIMENTAL
Intervention: O+G+tmp group
Number of subjects: 391
Study 21334096 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin (mean duration of treatment 8 weeks, range 6‐12 weeks)
Number of subjects: 2163
Study 21334096 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (mean duration of treatment 4 weeks, range 2‐6 weeks)
Number of subjects: 2163
Study 21334096 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 2163
Study 21334096 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin
Number of subjects: 2163
Study 19815540 — intervention group
Group type: EXPERIMENTAL
Intervention: dobutamine 2.5‐5.0 microg/kg/min
Number of subjects: 14
Study 19815540 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 14
Study 17083726 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic patients
Number of subjects: 39
Study 17083726 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe asthmatics on inhaled steroid treatment
Number of subjects: 39
Study 17083726 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 39
Study 15617307 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily (BID) for 4 weeks
Number of subjects: 20
Study 15617307 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% three times daily (TID) for 4 weeks
Number of subjects: 20
Study 11360849 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified and vertical maternal position (sitting and prone)
Number of subjects: 56
Study 11360849 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 56
Study 9258155 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicocele repair
Number of subjects: 124
Study 9258155 — intervention group
Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 124
Study 7871001 — intervention group
Group type: EXPERIMENTAL
Intervention: tropisetron 0.5 mg daily
Number of subjects: 91
Study 7871001 — intervention group
Group type: EXPERIMENTAL
Intervention: tropisetron 5 mg daily
Number of subjects: 91
Study 7871001 — intervention group
Group type: EXPERIMENTAL
Intervention: tropisetron 25 mg daily
Number of subjects: 91
Study 7871001 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 91
Study 7871001 — intervention group
Group type: EXPERIMENTAL
Intervention: tropisetron (all doses)
Number of subjects: 91
Study 3531149 — intervention group
Group type: EXPERIMENTAL
Intervention: Somofillina Ritardo
Number of subjects: 20
Study 3531149 — intervention group
Group type: COMPARATOR
Intervention: Other slow-release theophylline formulation
Number of subjects: 20
Study 30613992 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC removal and PN discontinuation at an enteral feed volume of 100 mL/kg/day
Number of subjects: 139
Study 30613992 — intervention group
Group type: COMPARATOR
Intervention: PICC removal and PN discontinuation at an enteral feed volume of 140 mL/kg/day
Number of subjects: 139
Study 29685112 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network intervention (training influential adolescents to promote physical activity)
Number of subjects: 190
Study 29685112 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 190
Study 24567316 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimony plus pentoxifylline
Number of subjects: 0
Study 24567316 — intervention group
Group type: COMPARATOR
Intervention: Antimony plus placebo
Number of subjects: 0
Study 22001758 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with tidal volume (V(T)) of 12 mL/kg ideal body weight with zero positive end‐expiratory pressure (PEEP)
Number of subjects: 26
Study 22001758 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation with tidal volume (V(T)) of 6 mL/kg ideal body weight with PEEP of 8 cm H(2)O
Number of subjects: 26
Study 20810669 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (250 mg/d)
Number of subjects: 26
Study 20810669 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 26
Study 17953380 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative preparation method of sequential thyroid defunctionalization (subgroup A)
Number of subjects: 476
Study 17953380 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative preparation method of sequential thyroid defunctionalization (subgroup B)
Number of subjects: 476
Study 17953380 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative preparation method of sequential thyroid defunctionalization (subgroup C)
Number of subjects: 476
Study 17953380 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative preparation method of sequential thyroid defunctionalization (subgroup D)
Number of subjects: 476
Study 17953380 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative preparation method of sequential thyroid defunctionalization (test group)
Number of subjects: 476
Study 17953380 — intervention group
Group type: COMPARATOR
Intervention: Antithyroid drugs and iodine preparation (control group)
Number of subjects: 476
Study 12062146 — intervention group
Group type: EXPERIMENTAL
Intervention: US bird experts
Number of subjects: 3
Study 12062146 — intervention group
Group type: COMPARATOR
Intervention: US undergraduates
Number of subjects: 3
Study 12062146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary Itza' Maya
Number of subjects: 3
Study 10219883 — intervention group
Group type: EXPERIMENTAL
Intervention: rec-GH therapy (C=0.6 IU/kg/week for C, CO=0.5 IU/kg/week, A=0.25 IU/kg/week) for 12 months (C and A) and 6 months (CO)
Number of subjects: 35
Study 10219883 — intervention group
Group type: COMPARATOR
Intervention: rec-GH therapy
Number of subjects: 35
Study 7838494 — intervention group
Group type: EXPERIMENTAL
Intervention: Single distal screw
Number of subjects: 178
Study 7838494 — intervention group
Group type: COMPARATOR
Intervention: Two distal screws
Number of subjects: 178
Study 1619179 — intervention group
Group type: COMPARATOR
Intervention: Placebo or different levels of supplemental vitamins
Number of subjects: 18
Study 1619179 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamin intake greater than or equal to 1.0 mg/day
Number of subjects: 18
Study 1619179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 intake at the current recommended dietary allowance (1.6 mg)
Number of subjects: 18
Study 6322681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (100 mg/kg per day in two doses for a minimum of 10 days)
Number of subjects: 45
Study 6322681 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy (ampicillin and chloramphenicol or gentamicin, pending sensitivity)
Number of subjects: 45
Study 6322681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 45
Study 6322681 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy
Number of subjects: 45
Study 30967642 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND) high in dietary fiber and whole grain
Number of subjects: 181
Study 30967642 — intervention group
Group type: COMPARATOR
Intervention: Average Danish (Western) Diet (ADD)
Number of subjects: 181
Study 30967642 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 181
Study 30216526 — intervention group
Group type: EXPERIMENTAL
Intervention: smartphone platform intervention with CHW reinforcement
Number of subjects: 98
Study 30216526 — intervention group
Group type: COMPARATOR
Intervention: usual prenatal care and printed educational materials (Control)
Number of subjects: 98
Study 25072436 — intervention group
Group type: EXPERIMENTAL
Intervention: DJBL treatment with dietary intervention
Number of subjects: 77
Study 25072436 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention (control)
Number of subjects: 77
Study 23731980 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0
Study 23731980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 0
Study 20629545 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho/EMD/DFDBA
Number of subjects: 47
Study 20629545 — intervention group
Group type: COMPARATOR
Intervention: EMD/DFDBA
Number of subjects: 47
Study 17507105 — intervention group
Group type: EXPERIMENTAL
Intervention: sarpogrelate (300 mg/day) plus aspirin (100 mg/day)
Number of subjects: 450
Study 17507105 — intervention group
Group type: COMPARATOR
Intervention: ticlopidine (200 mg/day) plus aspirin (100 mg/day)
Number of subjects: 450
Study 15963687 — intervention group
Group type: EXPERIMENTAL
Intervention: Group voice therapy
Number of subjects: 20
Study 15963687 — intervention group
Group type: COMPARATOR
Intervention: Control group (no voice therapy)
Number of subjects: 20
Study 12959938 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 DM with fatty liver
Number of subjects: 83
Study 12959938 — intervention group
Group type: COMPARATOR
Intervention: Type 2 DM without fatty liver
Number of subjects: 83
Study 10664525 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor MPV 2213ad, single dose of 100mg
Number of subjects: 16
Study 10664525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10664525 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor MPV 2213ad
Number of subjects: 16
Study 7640644 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg‐1) administered 2‐1/2 hrs prior to swim trial
Number of subjects: 0
Study 7640644 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 2‐1/2 hrs prior to swim trial
Number of subjects: 0
Study 2665027 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol (0.0012 mg/kg/day) solution bid for one week
Number of subjects: 30
Study 2665027 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (0.075 mg/kg/day) solution tid
Number of subjects: 30
Study 2665027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 363071 — intervention group
Group type: EXPERIMENTAL
Intervention: Butacote (enteric-coated phenylbutazone) 300 mg daily
Number of subjects: 25
Study 363071 — intervention group
Group type: COMPARATOR
Intervention: Naprosyn (naproxen) 750 mg daily
Number of subjects: 25
Study 30408722 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 969
Study 30408722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 969
Study 29229103 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 320/9 μg BID
Number of subjects: 1219
Study 29229103 — intervention group
Group type: COMPARATOR
Intervention: Formoterol DPI 9 μg BID
Number of subjects: 1219
Study 26317285 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 165
Study 26317285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 24707612 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail (PFN)
Number of subjects: 32
Study 24707612 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Hip Screw (DHS) plate
Number of subjects: 32
Study 21996470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=558)
Number of subjects: 1696
Study 21996470 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=449)
Number of subjects: 1696
Study 21996470 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=451)
Number of subjects: 1696
Study 21996470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=532)
Number of subjects: 1696
Study 21996470 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=423)
Number of subjects: 1696
Study 18433672 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of 0.2% ropivacaine 10 mL/h (group R, n = 22)
Number of subjects: 44
Study 18433672 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion of 0.9% NaCl 10 mL/h (group S, n = 22)
Number of subjects: 44
Study 16555138 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free and casein-free diet (GFCF)
Number of subjects: 15
Study 14556808 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid IL-18 levels in women with untreated endometriosis
Number of subjects: 76
Study 14556808 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal fluid IL-18 levels in control women
Number of subjects: 76
Study 14556808 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid IL-18 levels in women with superficial peritoneal implants
Number of subjects: 76
Study 14556808 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid IL-18 levels in women with deep peritoneal implants
Number of subjects: 76
Study 14556808 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid IL-18 levels in women with endometriomas
Number of subjects: 76
Study 14556808 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid IL-18 levels in women with stage I-II endometriosis
Number of subjects: 76
Study 14556808 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid IL-18 levels in women with stage III-IV endometriosis
Number of subjects: 76
Study 14556808 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid IL-18 levels in luteal phase
Number of subjects: 76
Study 11073017 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g elemental calcium daily)
Number of subjects: 552
Study 11073017 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre supplementation (3.5 g ispaghula husk)
Number of subjects: 552